drugset
drugset / Trial / NCT04046614

Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology

NCT04046614 ↗

Phase 1/2 Completed 56 enrolled AIO-Studien-gGmbH
NaSingle-groupOpen-labelTreatment

Summary

Determination of a safe dose for nintedanib+nivolumab combination therapy and the generation of exploratory efficacy data in pretreated patients with advanced or metastatic NSCLC of adenocarcinoma histology.

Timeline

Start
2018-05-25
Primary completion
2023-05-23
Completion
2023-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Nintedanib Small molecule — —
Subject Nivolumab Monoclonal antibody 240 mg —

Indications

lung adenocarcinoma